NGM’s Second Phase II Miss Raises Questions For Option Deal With Merck

 
• By Joseph Haas

NGM said a Merck-partnered C3 inhibiting antibody has failed a Phase II study in geographic atrophy, after the biotech’s wholly owned NASH candidate missed in a Phase IIb study in 2021.

Crash & Burn
NGM's stock price declined by 70% after the CATALINA data were unveiled • Source: Shutterstock

More from Clinical Trials

More from R&D